More than a year after an independent data monitoring committee (IDMC) suggested that Argos Therapeutics Inc. halt the pivotal phase III ADAPT trial of lead candidate rocapuldencel-T (roca-T, formerly AGS-003) for futility, the Durham, N.C.-based company threw in the towel and said it was exploring a range of strategic alternatives, including a potential merger or sale of the company.